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Abstract
Background: Bacterial vaginosis (BV) during pregnancy is a well-established risk factor for preterm birth and other
preterm pregnancy complications. Little is known about adverse neonatal outcomes associated with BV exposure in
full-term births, nor its influence on adverse outcomes independent of its effect on gestational age. The purpose of
this study was to examine the relationship between BV during pregnancy and adverse neonatal outcomes among
full-term and preterm infants.
Methods: We conducted a retrospective cohort study of Washington State mother/infant pairs from 2003-2013,
stratified by full-term (primary outcomes) and preterm births (secondary outcomes). BV-exposed and unexposed
women were frequency-matched based on year of delivery. BV exposure and adverse outcomes [assisted
ventilation/respiratory distress, neonatal intensive care unit (NICU) admission, neonatal sepsis, fetal mortality, and
infant mortality] were identified using birth certificates, ICD-9 codes from linked hospital records, and death
certificates. Associations between BV exposure and outcomes were assessed using multivariable Poisson regression,
adjusted for maternal demographics, gestational age, and other pregnancy complications, including infections.
Results: A total of 12,340 mother/infant pairs were included: 2,468 BV-exposed (2198 term, 267 preterm) and 9,872
BV unexposed (9156 term, 708 preterm). Among full-term infants, BV-exposed mothers were younger, more likely to
be Black or Hispanic, more likely to have had a sexually transmitted infection, and less likely to have a college
degree than unexposed mothers. Term BV exposed infants were more likely to have meconium at delivery.
Following adjustment, BV was associated with an increased risk of assisted ventilation/respiratory distress at birth
(aRR = 1.28, 95 % CI 1.02-1.61), NICU admission (aRR = 1.42, 95 % CI 1.11-1.82), and neonatal sepsis (aRR = 1.60, 95 %
CI 1.13-2.27) among full-term infants. These associations were independent of the presence of chorioamnionitis or
meconium. Among preterm infants, BV-exposure was associated with an increased risk for NICU admissions only
(aRR = 1.24, 95 % CI 1.04-1.46).
Conclusions: BV exposure during pregnancy is associated with adverse neonatal outcomes even among infants
born full-term. These findings amongst full-term infants are novel, and highlight neonatal implications of BV in
pregnancy independent of BV’s effect on preterm birth.
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Background
Bacterial vaginosis (BV), defined as a disturbance in the
natural vaginal microbiota characterized by reduced
Lactobacillus and overgrowth of anaerobic bacteria [1], is
found in 9 % to 23 % of pregnant women [2]. Symptoms
include vaginal discharge and malodor, but often women
who have BV are asymptomatic. BV during pregnancy is
an established risk factor for preterm delivery [1, 3–5] as
well as other adverse preterm pregnancy outcomes such
as premature rupture of membranes, low birth weight,
chorioamnionitis, and spontaneous abortion [1, 4, 5]. A
single cohort study of preterm infants suggests that BV is
associated with an increased risk of adverse neonatal
outcomes including: NICU admission, respiratory distress
at birth, requirement of assisted ventilation at birth, and
NICU stays lasting longer than 2 days [6]. Data on adverse
neonatal outcomes associated with BV among infants
born full-term is almost nonexistent.
We hypothesized that BV is associated with an increase
in adverse neonatal outcomes due to ascending infection
at all gestational ages and that the increased risks previ-
ously observed among preterm pregnancies are not solely
attributable to prematurity. The primary aim of this large
Washington State cohort study was to evaluate, among
full-term infants, the effects of BV on five fetal/infant
outcomes: assisted ventilation/respiratory distress at birth,
admission to neonatal intensive care unit (NICU),
neonatal sepsis, fetal mortality, and infant mortality. Our
secondary aims were to evaluate these same outcomes
among preterm (<37 weeks gestation) infants exposed and
unexposed to BV, as well as to reaffirm the relationship
between BV and preterm delivery among all infants.
Women included as BV-exposed in our study were likely
symptomatic women, and asymptomatic women were
likely disproportionately misclassified in the unexposed
group. However, this misclassification would only drive
findings toward the null - any association found in our
study would be perhaps, “only the tip of the iceberg”, or a
marker for an important underlying etiology related to BV
but not directly causal.
Methods
We conducted a population-based retrospective cohort
study using data from Washington State birth certificates
and birth hospitalizations from 2003-2013. These data
were extracted from the Birth Events Records Database
(BERD), a database linking more than 95 % of Washington
State birth certificate data with maternal and infant
hospitalization records from the statewide Comprehensive
Hospital Abstract Report System (CHARS) [7]. Infant
mortality was identified from death certificates issued
through 2014. While there is underreporting of birth com-
plications and maternal conditions on birth certificates
[8], the use of hospital discharge and death certificate data
improves the accuracy and completeness of both expo-
sures and outcomes in this study. Four of our 5 outcomes:
assisted ventilation/respiratory distress at birth, admission
to neonatal intensive care unit (NICU), fetal mortality,
and infant mortality are “hard outcomes” and it is highly
unlikely that they would be inaccurate. Neonatal sepsis,
our fifth outcome, is perhaps more prone to inaccurate
birth certificate reporting [8], but it is also likely to be cap-
tured in linked hospital discharge data, as the sensitivity of
ascertaining infection-related outcomes using ICD9 codes
is near perfect [9]. All data were de-identified, and the
study was determined to be exempt from review by the
Washington State Institutional Review Board.
Study population
We included all BV-exposed mothers who gave birth in
Washington State from 2003-2013 who met study criteria.
Women were considered BV-exposed if on the birth
certificate the “other” box under “Infections Present and/or
Treated During this Pregnancy” was checked and the
write-in space specified the infection as bacterial vaginosis
(e.g., “BV”, “Bac Vag”, or “B Vaginosis”). Additional exposed
women were identified using ICD-9 codes 616.10, 616.11,
and 646.63 from CHARS data. BV-unexposed women did
not have a write-in infection that could be identified as BV
nor any BV ICD-9 codes in their delivery hospitalization
records. We enrolled four unexposed women per exposed
woman, frequency-matched for the infant’s year of birth.
Non-singleton and births with a congenitally malformed
infant were excluded.
Primary outcome measures
We measured the risk of five fetal/infant outcomes:
assisted ventilation/respiratory distress at birth, NICU
admission, neonatal sepsis, fetal mortality, and infant
mortality. Outcomes were identified using a combination
of birth certificate checkboxes, ICD-9 codes from the
birth hospitalization record, and death certificates. If ei-
ther the box on the birth certificate was checked, or the
ICD-9 code was present, the outcome was considered to
have occurred. Assisted ventilation/respiratory distress is
coded on the birth certificate as “assisted ventilation
required immediately following birth” and was also eval-
uated using ICD-9 codes 768.5 (severe birth asphyxia)
and 769 (respiratory distress syndrome in a newborn).
NICU admission was identified via birth certificate check-
box. Neonatal sepsis was ascertained using ICD-9 codes
771.81 (septicemia [sepsis] of newborn) and 771.83
(bacteremia of newborn) and by birth certificate checkbox.
Because this study primarily used birth certificate data,
fetal deaths before 20 weeks gestation (where no birth or
death certificate would have been issued) were not
captured. Fetal mortality at 20 weeks or greater gestation
was identified from birth hospitalization records, ICD-9
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code V27.1, and linked death certificates. Infant mortality
is defined as death within one year of birth, and was
identified via linked birth and death certificates.
Statistical analyses
We used Poisson regression to calculate risk ratios with
95 % confidence intervals for all outcomes among sub--
cohorts of full-term infants (≥37 weeks gestation) and
preterm infants (<37 weeks gestation), as well as the
complete cohort. Gestational age was established from
the birth certificate, primarily from ultrasound dating in
the first or second trimester (N = 12,317); when this
variable was missing, we estimated gestational age using
the date of the mother’s last menstrual period (N = 23).
We established a priori that maternal age and maternal
race (White, Black, Hispanic, Asian, Native American,
Other) would be included in the models [3, 5, 10, 11].
We also controlled for gestational age when appropriate.
In addition, we considered the following as covariates:
maternal education (<high school, high school graduate/
some college, college degree); delivery method (cesarean
delivery or vaginal birth, either spontaneous or assisted);
prenatal smoking (yes/no); nulliparity (yes/no); birth
weight <2500 grams (yes/no); small for gestational age
among live born infants (lowest 10th percentile, calculated
from the BERD database from 1989-2002 based on Lipsky
et al.) [12]; sexually transmitted infection (STI; syphilis,
gonorrhea, chlamydia, or genital herpes) diagnosed and/or
treated during pregnancy (yes/no); presence of hyperten-
sion, diabetes, or pre-eclampsia during pregnancy (yes/no);
presence of chorioamnionitis (yes/no); and presence of
moderate or heavy meconium (yes/no). Covariates with
significant missing data were not included in the models. A
variable was considered to be a potential confounder if
controlling for the variable produced a >10 % change in
the risk estimate. Confounding was assessed separately in
the full-term and preterm sub-cohorts, as well in the entire
cohort for all outcomes. Confounders determined not to
be in the causal pathway were included in the model.
Significant associations between BV and the examined
outcomes were further explored with stratified analyses
evaluating our hypothesis that poor outcomes were likely
to be associated with an ascending infection.
All analyses were conducted using STATA 13 software
(Stata Corporation, College Station, Texas).
Results
We included and analyzed 12,340 mother/infant pairs.
Gestational age was missing for 11 infants; these partici-
pants were excluded from the full-term (N = 11,354) and
pre-term (N = 975) sub-cohort analyses but were
included for analyses of the full cohort. There were
2,198 term and 267 preterm mother/infant pairs identi-
fied that were BV exposed.
Demographic characteristics varied between BV
exposed and unexposed women (Table 1). Among full-
term birth, BV-exposed mother were significantly youn-
ger than unexposed mothers (<20 years: 14.7 % vs.
7.3 %), and more likely to be having their first birth
(47.2 % vs. 41.4 %). They were more likely to be Black
(10.7 % vs. 4.6 %) or Hispanic (19.0 % vs. 10.8 %), and
less likely to have a college degree (16.5 % vs. 36.1 %).
BV-exposed mothers were more likely to have smoked
during pregnancy (16.5 % vs. 10.1 %), less likely to have
had a cesarean delivery (21.7 % vs. 27.1 %), more likely
to have a small for gestational age infant (10.3 % vs.
8.6 %), less likely to have had at least adequate prenatal
care as indicated by the Kotelchuck index (59.6 % vs.
62.5 %), and more likely to have had an STI diagnosed
and/or treated during their pregnancy (13.5 % vs. 4.1 %).
Comorbid pregnancy conditions (diabetes, hypertension
and preeclampsia) were similar between BV-exposed and
BV-unexposed mothers. Term infants born to BV-exposed
mothers were more likely to have moderate or heavy
meconium (9.0 % vs. 5.6 %) than infants of unexposed
mothers. Preterm infants born to BV-exposed mothers
had a higher risk of chorioamnionitis (8.2 % vs. 5.8 %).
Other demographic characteristics were similar in the
full-term and preterm births, with the exception that
cesarean deliveries and low birth weight infants were
higher in the preterm births.
Among full-term infants, BV exposure was significantly
and positively associated with an approximately 28 %
increased risk of assisted ventilation at birth, a 42 %
increased risk for admission to NICU and a 60 % increased
risk for neonatal sepsis after adjusting for gestational age,
maternal age, and maternal race (Table 2). There was no
association with fetal or infant mortality. The presence of
an STI confounded the relationship between BV and fetal
mortality in the full-term births and was controlled for, but
presence of an STI did not confound any other outcomes
in term, preterm, or all births. Additionally, no other covar-
iates confounded the relationship between BV and any of
the outcomes examined. Among full-term births, the risk
ratio for the association of BV with neonatal sepsis was
higher in SGA infants (adjusted risk ratio [aRR] = 2.57,
95 % confidence interval [CI] 1.04, 6.40) than in AGA and
LGA infants (aRR = 1.46, 95 % CI 1.00, 2.13), but confi-
dence intervals are overlapping. Rates of chorioamnionitis
and meconium were higher in BV-exposed pregnancies,
but neither modified the relationship between BV and the
outcomes examined (Table 3).
Among preterm infants, BV exposure was associated
with a 24 % increased risk for admission to NICU after
adjusting for gestational age, maternal age, and maternal
race (Table 4). Assisted ventilation at birth, neonatal
sepsis, infant and neonatal mortality were not associated
with BV exposure.
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Among all infants, preterm birth was 55 % more likely to
occur in women with BV (Table 5). Assisted ventilation at
birth, admission to NICU, and neonatal sepsis were also
associated with BV exposure in the whole cohort. There was
an association between BV and 2nd trimester (20-28 weeks
gestation) fetal mortality (aRR = 10.42, 95 % CI 3.55, 30.61).
Table 1 Maternal characteristics of women with and without bacterial vaginosis during pregnancy, Washington State 2003-2013
Full Term (N = 11,354) Preterm (N = 975) Total (N = 12,340)
BV exposed BV unexposed BV exposed BV unexposed BV exposed BV unexposed
N = 2198 N = 9156 N = 267 N = 708 N = 2468 N = 9872
n % n % n % n % n % n %
Age (years)*
<20 324 14.7 666 7.3 39 14.6 56 7.9 363 14.7 723 7.3
20-24 784 35.7 2095 22.9 79 29.6 179 25.3 866 35.1 2278 23.1
25-29 620 28.2 2593 28.3 66 24.7 166 23.5 686 27.8 2760 28.0
30-34 317 14.4 2375 26.0 44 16.5 188 26.6 361 14.6 2564 26.0
35+ 153 7.0 1424 15.6 39 14.6 119 16.8 192 7.8 1544 15.6
Race/Ethnicity*
White 1268 58.8 6842 71.7 152 58.9 497 71.8 1422 58.8 6981 71.7
Black 231 10.7 416 4.6 21 8.1 36 5.2 252 10.4 452 4.6
Asian 183 8.5 939 10.4 28 10.9 64 9.3 212 8.8 1006 10.3
Hispanic 410 19.0 979 10.8 39 15.1 73 10.6 449 18.6 1054 10.8
Native American 62 2.9 218 2.4 18 7.0 22 3.2 80 3.3 240 2.5
Other 4 0.2 9 0.1 0 0.0 0 0.0 4 0.2 9 0.1
Education*
Less than H.S. 689 31.6 1639 18.1 89 34.1 148 21.4 779 31.9 1791 18.4
H.S. grad/some college 1132 51.9 4134 45.8 129 49.4 323 46.6 1263 51.7 4460 45.8
College graduate 360 16.5 3263 36.1 43 16.5 222 32.0 403 16.5 3486 35.8
Nulliparous* 3733 47.2 1035 41.4 118 45.2 309 45.2 1154 47.0 4045 41.7
Cesarean delivery* 477 21.7 2479 27.1 78 29.3 269 38.1 555 22.5 2751 27.9
Low Birth Weight (<2500 g)* 41 1.9 139 1.5 158 60.1 344 49.1 199 8.1 483 4.9
Small for gestational age 227 10.3 790 8.6 22 8.2 76 10.7 249 10.1 866 8.8
missing 0 (0) 12 (0.13) 20 (7.49) 15 (2.12) 23 (0.93) 35 (0.35)
Smoking* 360 16.5 921 10.1 42 15.9 84 12.0 404 16.5 1006 10.3
Kotelchuck Index
Inadequate 374 17.8 1203 15.2 29 14.2 85 16.7 403 17.5 1291 15.3
Intermediate 475 22.6 1763 22.3 39 19.1 76 14.9 514 22.3 1839 21.8
Adequate 899 42.7 3658 46.3 52 25.5 150 29.5 951 41.2 3808 45.2
Adequate Plus 356 16.9 1283 16.2 84 41.2 198 38.9 440 19.1 1481 17.6
missing 94 (4.3) 1249 (13.6) 63 (23.6) 199 (28.1) 160 (6.5) 1453 (14.7)
STI*† 296 13.5 379 4.1 34 12.7 42 5.9 330 13.4 422 4.3
Maternal comorbidities‡ 236 10.8 1022 11.3 53 20.0 184 26.3 289 11.7 1207 12.4
missing 2 (0.1) 92 (1.0) 2 (0.8) 7 (1.0) 5 (0.2) 99 (1.0)
Chorioamnionitis* 62 2.8 265 2.9 22 8.2 41 5.8 84 3.4 306 3.1
Meconium (moderate/heavy) 198 9.0 510 5.6 6 2.3 19 2.7 204 8.3 530 5.4
missing 4 (0.2) 98 (1.1) 20 (7.5) 26 (3.7) 25 (1.0) 126 (1.3)
BV bacterial vaginosis; H.S. High School, STI sexually transmitted infections
*Missing data not displayed, <3.5 % in all groups
†syphilis, gonorrhea, chlamydia, and/or genital herpes
‡hypertension, diabetes, and/or pre-eclampsia
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Discussion
Consistent with prior research, we found a strong
association between BV and risk for preterm birth [3, 5,
10, 11, 13]. More importantly, our primary study goal
was to assess term outcomes. We hypothesized that BV
would increase the risk for adverse neonatal outcomes,
even among infants born full-term. We found an associ-
ation between BV and an increased risk of neonatal
assisted ventilation/respiratory distress, admission to
NICU, and neonatal sepsis in the full cohort of term and
preterm infants, similar to a prior study [6]. But, notably
these findings persisted when analyses were restricted to
only term deliveries.
Our data demonstrate an association between BV
during pregnancy and poor neonatal outcomes at term
that has only been hinted at previously [4]. We had
hypothesized that poor neonatal outcomes could be due
to ascending infection during pregnancy that might
increase risks of chorioamnionitis or poor fetal growth,
which in turn might increase the risk of poor neonatal
outcomes. Meta-analyses previously showed a trend for
increased risk of neonatal sepsis associated with BV in
infants of all gestational ages, but results were non-
significant and sample sizes limited with an inability to
fully explore term outcomes [3, 5]. Data from a single
study, with a small sample of 151 term BV exposures
Table 2 Associations between bacterial vaginosis and adverse outcomes among full-term infants (37 weeks or greater gestation),
Washington State, 2003-2013, adjusted for gestational age, maternal age, and maternal race (N = 11,354)
BV exposed BV unexposed RR 95 % CI aRR 95 % CI
N = 2198 N = 9156
n % n %
Assisted ventilation at birth 100 4.6 331 3.6 1.26 1.01–1.57 1.28 1.02–1.61
Admission to NICU at birth 89 4.1 272 3.0 1.36 1.08–1.72 1.42 1.11–1.82
Neonatal sepsis 48 2.2 126 1.4 1.59 1.14–2.21 1.60 1.13–2.27
Fetal Mortality 3 0.1 13 0.1 0.96 0.27–3.37 1.15* 0.27–4.96
Infant mortality 4 0.2 24 0.3 0.69 0.24–2.00 0.39 0.12–1.28
BV bacterial vaginosis, RR risk ratio, aRR adjusted risk ratio, CI confidence interval, NICU neonatal intensive care unit
*further adjusted for presence of sexually transmitted infections (syphilis, gonorrhea, chlamydia, and/or genital herpes)
Table 3 Associations between bacterial vaginosis and adverse outcomes among full-term infants (37 weeks or greater gestation),
Washington State, 2003-2013 (N = 11,354), adjusted for gestational age, maternal age, and maternal race, and additionally adjusted
for the presence of chorioamnionitis or meconium
BV exposed BV unexposed aRR 95 % CI
N = 2198 N = 9156
n % n %
Assisted ventilation at birth 98 4.5 328 3.6 1.28 1.02–1.61
additionally adjusted for chorioamnionitis 98 4.5 328 3.6 1.28 1.02–1.61
additionally adjusted for meconium 98 4.5 328 3.7 1.22 0.97–1.53
Admission to NICU at birth 88 4.1 269 3.0 1.42 1.11–1.82
additionally adjusted for chorioamnionitis 88 4.1 269 3.0 1.45 1.13–1.85
additionally adjusted for meconium 88 4.1 267 3.0 1.34 1.05–1.72
Neonatal sepsis 48 2.2 125 1.4 1.60 1.13–2.27
additionally adjusted for chorioamnionitis 48 2.2 125 1.4 1.67 1.19–2.35
additionally adjusted for meconium 48 2.2 125 1.4 1.51 1.06–2.14
Fetal Mortality 3 0.1 12 0.1 1.15* 0.27–4.96
additionally adjusted for chorioamnionitis 3 0.1 12 0.1 1.14* 0.27–4.88
additionally adjusted for meconium 0 0.0 3 0.0 - -
Infant mortality 3 0.1 24 0.3 0.39 0.12–1.28
additionally adjusted for chorioamnionitis 3 0.1 24 0.3 0.39 0.12–1.27
additionally adjusted for meconium 3 0.1 23 0.3 0.40 0.12–1.34
BV bacterial vaginosis, aRR adjusted risk ratio, CI confidence interval, NICU neonatal intensive care unit
*further adjusted for presence of sexually transmitted infections (syphilis, gonorrhea, chlamydia, and/or genital herpes)
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and 6 instances of infectious morbidity, suggests a
modest association between infectious morbidity and BV
exposure early in pregnancy among full-term infants;
however, this association was not formally examined [4].
BV has been associated with chorioamnionitis in
primarily preterm cohorts [14, 15], and chorioamnionitis
is associated with neonatal sepsis in both term and
preterm infants [16, 17]. Our study of 12,340 infants
showed significant associations between BV and neonatal
sepsis, both in the complete cohort and in the subset of
full-term infants that included 2,198 BV-exposed
mother/infant pairs. BV-exposed women delivering at
term also had higher rates of meconium, which has been
associated with in-utero bacteria [18] and worse
neonatal outcomes [19]. However, when the presence of
meconium and/or chorioamnionitis were included in
our models, the risk for adverse outcomes persisted,
suggesting that the association between BV and neonatal
compromise is not due to meconium aspiration or the
direct effects of chorioamnionitis. BV is associated with
upper genital tract infection in both pregnant [20] and
non-pregnant [21] women, thus sub-clinical infection
could be one mechanism for the poor neonatal
outcomes observed.
Others have not evaluated full-term births for the
association of BV with SGA or LBW. Among full-term
infants in our cohort, BV-exposed infants were more
likely to be SGA, but not more likely than unexposed
infants to have LBW. In our full cohort, BV-exposed
infants were more likely to be SGA or LBW, confirming
previous reports of this association [15, 22, 23]. In other
studies among preterm infants, BV has been associated
with LBW [1]. In a cohort of late preterm (>33 weeks)
and term infants, SGA was associated with increased
NICU admission, low Apgar scores and composite
neonatal morbidity [24]. In our study, SGA infants were
at greater risk of NICU admission when born preterm,
and greater risk of neonatal sepsis when born full-term,
but these increased risks were not statistically different
from LGA and AGA infants.
The increased risk of NICU admissions and respiratory
distress among full-term infants exposed to BV that we
observed in our cohort has not been previously described,
to our knowledge. In a small cohort of preterm infants,
the proportions of infants with respiratory distress,
requirement of intermittent positive pressure ventilation,
admission to NICU, and NICU stays over two days was
higher among BV exposed than among BV-unexposed
Table 4 Associations between bacterial vaginosis and adverse outcomes among preterm infants (less than 37 weeks gestation),
Washington State, 2003-2013, adjusted for gestational age, maternal age, and maternal race (N = 975)
BV exposed BV unexposed RR 95 % CI aRR 95 % CI
N = 267 N = 708
n % n %
Assisted ventilation at birth 51 19.1 94 13.3 1.44 1.05–1.96 1.23 0.89–1.73
Admission to NICU at birth 124 50.4 246 36.0 1.40 1.20–1.64 1.24 1.04–1.46
Neonatal sepsis 47 17.6 82 11.6 1.52 1.09–2.11 1.31 0.91–1.89
Fetal Mortality 21 7.9 21 3.0 2.65 1.47–4.78 1.25 0.67–2.33
Infant mortality 17 6.9 21 3.1 2.26 1.21–4.22 1.10 0.66–1.84
BV bacterial vaginosis, RR risk ratio, aRR adjusted risk ratio, CI confidence interval, NICU neonatal intensive care unit
Table 5 Associations between bacterial vaginosis and adverse outcomes among all infants, Washington State, 2003-2013, adjusted
for maternal age and race (N = 12,340)
BV exposed BV unexposed RR 95 % CI aRR 95 % CI
N = 2468 N = 9872
n % n %
Preterm birth 267 10.8 708 7.2 1.51 1.32–1.72 1.55 1.34–1.78
Assisted ventilation at birth 151 6.1 425 4.3 1.42 1.19–1.70 1.45 1.21–1.75
Admission to NICU at birth 213 8.7 519 5.3 1.65 1.42–1.92 1.73 1.47–2.03
Neonatal sepsis 95 3.9 209 2.1 1.82 1.43–2.31 1.86 1.44–2.41
Fetal Mortality 25 1.0 35 0.4 2.86 1.71–4.76 2.79* 1.54–5.05
2nd trimester 16 0.7 7 0.1 12.22 4.29–34.79 10.42* 3.55–30.61
3rd trimester 9 0.4 28 0.3 1.49 0.65–3.40 1.31* 0.55–3.11
Infant mortality 21 0.9 45 0.5 1.89 1.12–3.15 1.61 0.90–2.90
BV bacterial vaginosis, RR risk ratio, aRR adjusted risk ratio, CI confidence interval, NICU neonatal intensive care unit
*further adjusted for presence of a maternal comorbidity (hypertension, diabetes, and/or pre-eclampsia)
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pregnancies (uncontrolled analyses) [6]. We confirmed
the association between BV and NICU admission in
preterm infants, controlling for gestational age and several
possible confounders, strengthening the likelihood that
this association is biologically true.
We did not find an increased risk for term perinatal
mortality associated with BV and, to our knowledge, this
has not been studied previously. BV has not been associ-
ated with perinatal mortality in previous meta-analyses
of primarily preterm cohorts [3]. Perinatal mortality was
not associated with overall fetal or infant mortality in
our full cohort. However, when we evaluated mortality
by trimester, the risk of 2nd trimester fetal mortality was
increased, supporting meta-analyses that reported a
6-fold increased risk for loss between 14-24 weeks in
women diagnosed with BV during early pregnancy [3].
Our study has strengths and limitations. It was large,
population-based, and rich in covariates, with little
missing data. While birth certificate sensitivity is poor
for some variables [8, 25], we increased ascertainment of
exposures and outcomes by using both birth certificates
and linked hospital records. Since routine screening for
BV is not standard of care, cases identified were likely
symptomatic, which may limit this study’s findings to
cases of symptomatic BV. While asymptomatic cases
may be under-diagnosed, including asymptomatic
BV-exposed mothers among the unexposed would bias
results towards the null. We did not have data on BV
treatment in exposed women or the trimester that BV
was diagnosed. If BV treatment tempers the increased
risk of the poor neonatal outcomes associated with BV,
associations may be even greater than reported here.
Furthermore, associations may differ according to the
timing of BV treatment. Further studies are needed to
address these questions. Additionally, 68 % of the
women were White, limiting the generalizability of our
findings. A large proportion of women were nulliparous.
But as all data are de-identified, mothers who gave birth
more than once during the study period may have been
included multiple times, potentially introducing a
clustering bias we are unable to address. Lastly, our
study shows an association, but cannot confirm a causal
relationship between BV and poor outcomes among
term deliveries.
Conclusions
BV during pregnancy appears to increase the risk for
adverse neonatal outcomes through mechanisms
independent of BV’s effect on timing of delivery. These
findings may have significant clinical implications if con-
firmed by other studies, but several questions remain,
including the importance of timing of the exposure and
the mechanism for these associations. While treatment
of BV during pregnancy has not succeeded in reducing
preterm birth [26, 27], treatments targeted specifically at
improving term neonatal outcomes have not been
explored as thoroughly. The Maternal Fetal Medicine
Unit's treatment trial for asymptomatic BV between 16
and 24 weeks did not show a difference in birthweight,
NICU admission, neonatal sepsis, or neonatal death,
though data were only shown for the first outcome. The
sample size of the trial was only 1,953, thus it may not
have had adequate power to detect differences in these
uncommon outcomes [27]. A Cochrane review [28] of
seven randomized clinical trials on antibiotic prophylaxis
during pregnancy for women at high risk of preterm birth
had inadequate power to study the effect of prophylaxis on
neonatal sepsis, did not restrict analyses to women with
BV, did not report on NICU admission, and did not focus
on term deliveries. There are very few prior studies directly
relevant to our findings - an increased risk of neonatal
assisted ventilation/respiratory distress, admission to
NICU, and neonatal sepsis among BV exposed infants born
at term. Our findings suggest that any study evaluating the
vaginal microbiota in pregnancy should include neonatal
outcomes as an endpoint, and expand our understanding
of BV associated outcomes in preterm infants to term
deliveries.
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